BE2014C017I2 - - Google Patents
Info
- Publication number
- BE2014C017I2 BE2014C017I2 BE2014C017C BE2014C017C BE2014C017I2 BE 2014C017 I2 BE2014C017 I2 BE 2014C017I2 BE 2014C017 C BE2014C017 C BE 2014C017C BE 2014C017 C BE2014C017 C BE 2014C017C BE 2014C017 I2 BE2014C017 I2 BE 2014C017I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17150999 | 1999-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2014C017I2 true BE2014C017I2 (US06811534-20041102-M00003.png) | 2019-05-21 |
Family
ID=15924444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2014C017C BE2014C017I2 (US06811534-20041102-M00003.png) | 1999-06-17 | 2014-03-04 |
Country Status (27)
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US20040224989A1 (en) * | 1999-01-29 | 2004-11-11 | Barberich Timothy J. | S-lansoprazole compositions and methods |
| TWI289557B (en) * | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| DE60020967T2 (de) * | 1999-06-30 | 2006-05-04 | Takeda Pharmaceutical Co. Ltd. | Kristalle von lansoprazole |
| ES2273829T3 (es) | 2000-04-28 | 2007-05-16 | Takeda Pharmaceutical Company Limited | Procedimiento para producir derivado de sulfoxido opticamente activo. |
| DE60131649T2 (de) * | 2000-05-15 | 2008-10-30 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung eines kristalls |
| CA2417311C (en) | 2000-08-04 | 2012-07-10 | Takeda Chemical Industries, Ltd. | Crystalline alkali metal salts of lansoprazole and their production and use |
| KR20100002278A (ko) * | 2000-12-01 | 2010-01-06 | 다케다 야쿠힌 고교 가부시키가이샤 | (ｒ)- 또는 (ｓ)-란소프라졸의 결정 |
| PT1459737E (pt) | 2001-10-17 | 2012-11-26 | Takeda Pharmaceutical | Grânulos contendo um composto químico instável em meio ácido em concentração elevada |
| KR100467100B1 (ko) * | 2002-03-20 | 2005-01-24 | 일양약품주식회사 | 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법 |
| CN1681802A (zh) * | 2002-03-27 | 2005-10-12 | 特瓦制药工业有限公司 | 兰索拉唑多晶型和其制备方法 |
| US8697094B2 (en) | 2002-10-16 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| KR100714375B1 (ko) | 2003-03-24 | 2007-05-02 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 술폭시드 유도체 또는 그 염의 아몰퍼스의 제조방법 |
| US20070101907A1 (en) * | 2003-06-20 | 2007-05-10 | Ch Chemical (Pty) Ltd. | Liner |
| US20050031700A1 (en) * | 2003-07-18 | 2005-02-10 | Sanatarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| WO2005007115A2 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
| EP1718303A4 (en) * | 2004-02-10 | 2010-09-01 | Santarus Inc | COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG |
| CA2561700A1 (en) * | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| EP1768668A2 (en) * | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
| CA2579665C (en) | 2004-09-13 | 2014-03-18 | Takeda Pharmaceutical Company Limited | Method and apparatus for producing oxidized compound |
| EP2275088B2 (en) | 2005-02-25 | 2018-09-26 | Takeda Pharmaceutical Company Limited | Method for producing granules |
| ES2259269B1 (es) | 2005-03-03 | 2007-11-01 | Esteve Quimica, S.A. | Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos. |
| EP1934201A1 (en) * | 2005-10-06 | 2008-06-25 | Auspex Pharmaceuticals Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| SG184754A1 (en) | 2005-12-28 | 2012-10-30 | Takeda Pharmaceutical | Controlled release solid preparation |
| KR100758600B1 (ko) | 2006-01-05 | 2007-09-13 | 주식회사 대웅제약 | 란소프라졸 결정형 ａ의 제조방법 |
| US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| WO2008068767A2 (en) * | 2006-12-07 | 2008-06-12 | Hetero Drugs Limited | A novel crystalline form of lansoprazole |
| JP5366558B2 (ja) | 2006-12-28 | 2013-12-11 | 武田薬品工業株式会社 | 口腔内崩壊性固形製剤 |
| US8173158B2 (en) * | 2007-10-12 | 2012-05-08 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treating gastrointestinal disorders independent of the intake of food |
| WO2009087672A1 (en) * | 2007-12-18 | 2009-07-16 | Watson Pharma Private Limited | A process for preparation of stable amorphous r-lansoprazole |
| EP2292612A3 (en) * | 2007-12-31 | 2011-05-04 | Takeda Pharmaceutical Company Limited | Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole |
| PE20091680A1 (es) * | 2008-03-10 | 2009-11-16 | Takeda Pharmaceutical | Cristal de compuestos de bencimidazol |
| PE20091620A1 (es) * | 2008-03-11 | 2009-11-12 | Takeda Pharmaceutical | Preparacion solida de desintegracion oral |
| CA2717578A1 (en) * | 2008-03-18 | 2009-09-24 | Dr. Reddy's Laboratories Ltd. | Dexlansoprazole process and polymorphs |
| US20090263475A1 (en) * | 2008-04-21 | 2009-10-22 | Nagaraju Manne | Dexlansoprazole compositions |
| EP2303868A2 (en) | 2008-05-14 | 2011-04-06 | Watson Pharma Private Limited | Stable r(+)-lansoprazole amine salt and a process for preparing the same |
| UY32008A (es) * | 2008-07-28 | 2010-02-26 | Takeda Pharmaceutical | Composición farmacéutica |
| WO2010039885A2 (en) * | 2008-09-30 | 2010-04-08 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of dexlansoprazole |
| IT1391758B1 (it) * | 2008-11-11 | 2012-01-27 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo amorfo |
| WO2010056059A2 (en) * | 2008-11-14 | 2010-05-20 | Hanmi Pharm. Co., Ltd. | Novel crystalline dexlansoprazole and pharmaceutical composition comprising same |
| IT1391776B1 (it) * | 2008-11-18 | 2012-01-27 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo |
| IT1392813B1 (it) * | 2009-02-06 | 2012-03-23 | Dipharma Francis Srl | Forme cristalline di dexlansoprazolo |
| US20110009637A1 (en) * | 2009-02-10 | 2011-01-13 | Dario Braga | Crystals of Dexlansoprazole |
| WO2011004387A2 (en) * | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | Process for the preparation of dexlansoprazole polymorphic forms |
| IT1395118B1 (it) * | 2009-07-29 | 2012-09-05 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo cristallino |
| IN2012DN05142A (US06811534-20041102-M00003.png) | 2009-11-12 | 2015-10-23 | Pharma Trophix Inc | |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| CN102108076B (zh) * | 2009-12-23 | 2014-07-23 | 江苏豪森医药集团有限公司 | 制备无定形右兰索拉唑的方法 |
| AU2011210328A1 (en) | 2010-01-29 | 2012-08-16 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline forms of dexlansoprazole |
| US20110189271A1 (en) * | 2010-02-02 | 2011-08-04 | Vishal Lad | Pharmaceutical formulations of acid-labile drugs |
| US8853411B2 (en) | 2010-03-31 | 2014-10-07 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
| CA2795056C (en) | 2010-03-31 | 2015-03-24 | Ranbaxy Laboratories Limited | Salts of dexlansoprazole and their preparation |
| EP2384746A3 (en) | 2010-05-05 | 2012-03-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Dual release oral tablet compositions of dexlansoprazole |
| EP2384747A3 (en) | 2010-05-05 | 2012-01-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral Tablet Compositions Of Dexlansoprazole |
| EP2384745A3 (en) | 2010-05-05 | 2012-01-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Modified release pharmaceutical compositions of dexlansoprazole |
| US20130216617A1 (en) | 2010-06-29 | 2013-08-22 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
| KR101908748B1 (ko) | 2010-12-03 | 2018-10-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 구강내 붕괴정 |
| SG10201602311XA (en) | 2010-12-27 | 2016-04-28 | Takeda Pharmaceutical | Orally disintegrating tablet |
| WO2012095859A1 (en) * | 2011-01-12 | 2012-07-19 | Hetero Research Foundation | Polymorphs of dexlansoprazole salts |
| WO2012104805A1 (en) | 2011-02-01 | 2012-08-09 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
| WO2012111024A1 (en) | 2011-02-18 | 2012-08-23 | Suven Nishtaa Pharma Pvt Ltd | Pharmaceutical compositions of dexlansoprazole |
| AU2012274967A1 (en) * | 2011-06-21 | 2014-01-23 | Sun Pharmaceutical Industries Limited | Process for the preparation of dexlansoprazole |
| CN102875531B (zh) * | 2011-07-15 | 2015-08-19 | 上海睿智化学研究有限公司 | 一种(r)-兰索拉唑无水晶型及其制备方法 |
| CN102875530A (zh) * | 2011-07-15 | 2013-01-16 | 上海睿智化学研究有限公司 | 一种(r)-兰索拉唑叔丁胺盐及其晶型和制备方法 |
| CN102875532B (zh) * | 2011-07-15 | 2015-05-13 | 上海睿智化学研究有限公司 | 一种(r)-兰索拉唑异丙胺盐及其晶型和制备方法 |
| CN102234265B (zh) * | 2011-08-08 | 2013-11-20 | 天津市汉康医药生物技术有限公司 | 兰索拉唑化合物 |
| SG11201402400YA (en) | 2011-11-30 | 2014-06-27 | Takeda Pharmaceutical | Dry coated tablet |
| US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
| WO2013140120A1 (en) | 2012-03-22 | 2013-09-26 | Cipla Limited | Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole |
| WO2013179194A1 (en) | 2012-05-31 | 2013-12-05 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline dexlansoprazole |
| CN103709139B (zh) * | 2012-10-09 | 2016-12-21 | 上海汇伦生命科技有限公司 | 无水右兰索拉唑的制备方法 |
| CN104177333A (zh) * | 2013-05-24 | 2014-12-03 | 四川海思科制药有限公司 | 一种理化性质稳定的(r)-2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1h-苯并咪唑 |
| CN104650035A (zh) * | 2013-11-25 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 右兰索拉唑倍半水合物化合物 |
| CN103664889B (zh) * | 2013-12-19 | 2014-11-19 | 悦康药业集团有限公司 | 一种兰索拉唑化合物 |
| WO2015155307A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and proton pump inhibitors |
| WO2015155281A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
| CN104844576B (zh) * | 2015-04-28 | 2017-03-08 | 山东罗欣药业集团股份有限公司 | 一种兰索拉唑或右旋兰索拉唑晶型化合物及其制备方法 |
| CN104829594A (zh) * | 2015-05-15 | 2015-08-12 | 苗怡文 | 一种治疗胃溃疡的药物兰索拉唑化合物 |
| CN105017218A (zh) * | 2015-07-01 | 2015-11-04 | 合肥安德生制药有限公司 | 一种右兰索拉唑晶型及其制备方法 |
| CN104958276A (zh) * | 2015-07-30 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗胃溃疡的药物兰索拉唑组合物胶囊 |
| CN104997738A (zh) * | 2015-08-10 | 2015-10-28 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗胃病的药物兰索拉唑组合物干混悬剂 |
| CN105399728B (zh) * | 2015-12-20 | 2017-11-28 | 寿光富康制药有限公司 | 一种适用于工业化生产的右兰索拉唑的处理方法 |
| CN108164507A (zh) * | 2016-12-07 | 2018-06-15 | 天津药物研究院有限公司 | 一种右兰索拉唑单晶及其制备方法和用途 |
| TR201701461A2 (tr) | 2017-01-31 | 2018-08-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dekslansoprazolün Enterik Kaplı Farmasötik Kompozisyonları |
| CN106866630B (zh) * | 2017-04-01 | 2018-08-07 | 上海华源医药科技发展有限公司 | 一种右兰索拉唑的制备方法 |
| CN107011329A (zh) * | 2017-05-05 | 2017-08-04 | 广州大光制药有限公司 | 兰索拉唑一水合物晶型及其结晶制备方法 |
| CN108794450B (zh) * | 2018-07-24 | 2022-08-19 | 浙江恒康药业股份有限公司 | 制备无定型右旋兰索拉唑的方法 |
| WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| DK171989B1 (da) * | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler |
| DE4035455A1 (de) | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | Enantiomerentrennung |
| SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| GB9423968D0 (en) * | 1994-11-28 | 1995-01-11 | Astra Ab | Resolution |
| HRP960232A2 (en) | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
| US5840737A (en) * | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| AU5652698A (en) | 1996-11-12 | 1998-06-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors |
| TW385306B (en) * | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| WO1998022118A1 (en) * | 1996-11-22 | 1998-05-28 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid |
| SE510666C2 (sv) | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| AU2481899A (en) | 1998-01-30 | 1999-08-16 | Sepracor, Inc. | S-lansoprazole compositions and methods |
| JP2002501897A (ja) | 1998-01-30 | 2002-01-22 | セプラコール， インク． | Ｒ−ランソプラゾール組成物及び方法 |
| AU3596199A (en) * | 1998-05-06 | 1999-11-23 | Kobenhavns Universitet | Treatment of celiac disease |
| TWI289557B (en) * | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| JP3283252B2 (ja) * | 1999-06-17 | 2002-05-20 | 武田薬品工業株式会社 | ベンズイミダゾール化合物の結晶 |
| DE60020967T2 (de) * | 1999-06-30 | 2006-05-04 | Takeda Pharmaceutical Co. Ltd. | Kristalle von lansoprazole |
| CN1117747C (zh) * | 2000-06-19 | 2003-08-13 | 中国科学院成都有机化学研究所 | 光学纯兰索拉唑的制备方法 |
| US8697094B2 (en) * | 2002-10-16 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| KR100714375B1 (ko) * | 2003-03-24 | 2007-05-02 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 술폭시드 유도체 또는 그 염의 아몰퍼스의 제조방법 |
| CA2591983A1 (en) * | 2004-12-20 | 2006-06-29 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions comprising amorphous benzimidazole compounds |
| WO2006067599A2 (en) * | 2004-12-23 | 2006-06-29 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
| US20060210637A1 (en) * | 2005-03-17 | 2006-09-21 | Qpharma, Llc | Stable tablet dosage forms of proton pump inhibitors |
| WO2009087672A1 (en) * | 2007-12-18 | 2009-07-16 | Watson Pharma Private Limited | A process for preparation of stable amorphous r-lansoprazole |
-
2000
- 2000-05-30 TW TW090111098A patent/TWI289557B/zh not_active IP Right Cessation
- 2000-05-30 TW TW089110444A patent/TWI275587B/zh not_active IP Right Cessation
- 2000-06-02 MY MYPI20002497 patent/MY125399A/en unknown
- 2000-06-14 AR ARP000102917A patent/AR031069A1/es not_active Application Discontinuation
- 2000-06-15 IL IL14599600A patent/IL145996A0/xx unknown
- 2000-06-15 WO PCT/JP2000/003880 patent/WO2000078745A2/en active Application Filing
- 2000-06-15 ES ES00937235T patent/ES2300265T3/es not_active Expired - Lifetime
- 2000-06-15 PL PL352193A patent/PL201068B1/pl unknown
- 2000-06-15 HU HU0201659A patent/HU229067B1/hu active Protection Beyond IP Right Term
- 2000-06-15 DE DE60038481T patent/DE60038481T2/de not_active Expired - Lifetime
- 2000-06-15 MX MXPA01012642A patent/MXPA01012642A/es active IP Right Grant
- 2000-06-15 US US09/674,624 patent/US6462058B1/en not_active Expired - Lifetime
- 2000-06-15 KR KR10-2003-7009783A patent/KR100514204B1/ko active IP Right Grant
- 2000-06-15 DK DK00937235T patent/DK1129088T3/da active
- 2000-06-15 KR KR10-2000-7013512A patent/KR100407847B1/ko active IP Right Grant
- 2000-06-15 DK DK08151945.6T patent/DK1977751T3/da active
- 2000-06-15 AU AU52478/00A patent/AU778820B2/en not_active Expired
- 2000-06-15 EP EP08151945.6A patent/EP1977751B1/en not_active Expired - Lifetime
- 2000-06-15 PT PT00937235T patent/PT1129088E/pt unknown
- 2000-06-15 CN CNB008090637A patent/CN1150186C/zh not_active Expired - Lifetime
- 2000-06-15 CA CA2375201A patent/CA2375201C/en not_active Expired - Lifetime
- 2000-06-15 BR BRPI0011674A patent/BRPI0011674B8/pt not_active IP Right Cessation
- 2000-06-15 KR KR10-2000-7013530A patent/KR100537029B1/ko active IP Right Grant
- 2000-06-15 SI SI200030990T patent/SI1129088T1/sl unknown
- 2000-06-15 NZ NZ515702A patent/NZ515702A/en not_active IP Right Cessation
- 2000-06-15 EP EP00937235A patent/EP1129088B1/en not_active Expired - Lifetime
- 2000-06-15 ES ES08151945T patent/ES2426985T3/es not_active Expired - Lifetime
- 2000-06-15 AT AT00937235T patent/ATE391126T1/de active
- 2000-06-15 EP EP20100177981 patent/EP2343289A1/en not_active Withdrawn
- 2000-06-15 PT PT81519456T patent/PT1977751E/pt unknown
- 2000-06-15 WO PCT/JP2000/003881 patent/WO2004083200A1/en active Application Filing
-
2001
- 2001-09-29 HK HK01106916A patent/HK1038227A1/xx not_active IP Right Cessation
- 2001-10-10 ZA ZA200108331A patent/ZA200108331B/en unknown
- 2001-10-17 IL IL145996A patent/IL145996A/en not_active IP Right Cessation
- 2001-12-13 NO NO20016087A patent/NO321168B1/no not_active IP Right Cessation
-
2002
- 2002-09-13 US US10/243,329 patent/US6664276B2/en not_active Expired - Lifetime
-
2003
- 2003-09-04 US US10/655,114 patent/US6939971B2/en not_active Expired - Lifetime
-
2005
- 2005-06-10 US US11/149,903 patent/US7339064B2/en not_active Expired - Lifetime
-
2008
- 2008-01-07 US US12/006,845 patent/US7569697B2/en not_active Expired - Fee Related
- 2008-06-26 CY CY20081100671T patent/CY1110384T1/el unknown
-
2009
- 2009-02-26 US US12/393,409 patent/US7737282B2/en not_active Expired - Fee Related
- 2009-04-01 HK HK09103096.8A patent/HK1123985A1/xx not_active IP Right Cessation
-
2010
- 2010-04-30 US US12/771,486 patent/US8030333B2/en not_active Expired - Fee Related
- 2010-12-15 AR ARP100104648A patent/AR079473A2/es not_active Application Discontinuation
-
2011
- 2011-09-01 US US13/223,988 patent/US20110319450A1/en not_active Abandoned
-
2012
- 2012-08-22 US US13/591,992 patent/US8552198B2/en not_active Expired - Fee Related
-
2013
- 2013-09-06 US US14/020,286 patent/US8884019B2/en not_active Expired - Fee Related
- 2013-10-09 CY CY20131100882T patent/CY1114485T1/el unknown
- 2013-11-26 AR ARP130104346A patent/AR093609A2/es unknown
-
2014
- 2014-03-04 BE BE2014C017C patent/BE2014C017I2/fr unknown
- 2014-10-07 US US14/508,651 patent/US9145389B2/en not_active Expired - Fee Related
- 2014-11-12 AR ARP140104252A patent/AR100473A2/es not_active Application Discontinuation
-
2015
- 2015-12-28 AR ARP150104310A patent/AR103295A2/es not_active Application Discontinuation
